A study presented at the American Association for Cancer Research Annual Meeting by the University of Colorado Cancer Center describes the ways that cancer cells have evolved to resist the drug LOXO-101, currently being evaluated in phase I and II clinical trials. This discovery could lead to new ways to counter the mechanisms that cancer cells use.